Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Evotec AG (EVO) Stock Price & Analysis
153 Followers
EVO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.94 - $13.49
Previous Close$4.78
Volume27.69K
Average Volume (3M)153.94K
Market Cap
$1.67B
Enterprise Value$1.86B
Total Cash (Recent Filing)€319.38M
Total Debt (Recent Filing)€506.67M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 14, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding353,905,306
10 Day Avg. Volume109,445
30 Day Avg. Volume153,936
Standard Deviation0.14
R-Squared0.28
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.78
Price to Sales (P/S)2.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.75Price Target Upside62.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Evotec AG News
PremiumCompany Announcements
Evotec AG Navigates Q1 Challenges, Eyes Growth
Bulls Say, Bears Say
Bulls Say
Order GrowthOrders in Discovery up by 70%, which the Discovery business representing a ~70% share of the Shared R&D segment, would lead to the revenue recovery in late 2024.
Partnership ExpansionEvotec extended its partnership with Bristol Myers Squibb in iPSC-based neurodegeneration and targeted protein degradation for an additional 8 years.
Revenue And EBITDA GrowthThe company guided the group revenues to grow by a double-digit percentage in 2024 (€781M in 2023) and adjusted group EBITDA expected to grow by a mid-double-digit percentage (€66.4M in 2023).
Bears Say
ExpensesEvotec would close the site in Orth, Austria, cut out the gene therapy program, and be guided to have a mid-single to low double-digit percentage reduction of unpartnered R&D expenses for the rest of 2024.
Market ConditionsShared R&D revs came in at €155.2M (-23% y/y) in Q1, the drop largely due to persistent headwinds for transactional business generated by the challenging market.
RevenueEvotec generated a total revenue of €208.7M in 1Q24, a decrease of 2.3% YoY from €213.6M in the corresponding period last year.
---
Ownership Overview
0.00%
Insiders
0.17% Mutual Funds
1.34% Other Institutional Investors
98.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $3.94 and its highest was $13.49 in the past 12 months.
What is Evotec AG’s market cap?
Currently, no data Available
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Aug 14, 2024 which is in 27 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -$0.02.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,106,780 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
---
Evotec AG Stock Smart Score
Company Description
Evotec AG
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
---
EVO Company Deck
---
EVO Earnings Call
Q1 2024
0:00 / 0:00
---
EVO Stock 12 Month Forecast
Average Price Target
$7.75
▲(62.13% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Arrowhead Pharmaceuticals
―
Bluebird Bio
―
Sarepta Therapeutics
―
Best Analysts Covering EVO
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-28.90%
reiterated a buy rating 12 months ago
Copying James Quigley's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -28.90% per trade.
---